Three things to know:
1. Axial spondyloarthritis primarily affects the sacroiliac joints and the spine, resulting in chronic inflammatory back pain and fatigue.
2. The drug is cleared to treat patients who show signs of inflammation but have not responded to conventional therapy.
3. This is the fourth indication for Taltz. Health Canada has also cleared the drug for plaque psoriasis, psoriatic arthritis and ankylosing spondylitis.
More articles on spine:
A simple solution to the health insurance marketplace: Authorize interstate competition
Where orthopedic PE partnerships stand in 2020
Facet joint replacement, stem cells & AR: 9 surgeons discuss new technologies
At the Becker’s 32nd Annual Meeting: The Business and Operations of ASCs, taking place October 29-31 in Chicago, ASC leaders, surgeons and healthcare executives will explore strategies to drive growth, enhance operational performance, navigate reimbursement challenges and prepare for the future of ambulatory surgery. Apply for complimentary registration now.
